|
AU2013201880A1
|
|
Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one
|
|
WO2010136778A1
|
|
Dibenzothiophene derivatives as dna- pk inhibitors
|
|
AU2009300866A1
|
|
Pharmaceutical formulation 514
|
|
CN101821242A
|
|
4- [3- (4-cyclopropanecarbonyl-piperazine-i-carbony_, -fluoro-benzyl] -2h-phthalaz in-1-one
|
|
BRPI0814797A2
|
|
Dna-pk inhibitors
|
|
ZA200804193B
|
|
4-heteroarymethyl substituted phthalazinone derivatives
|
|
TW200900396A
|
|
Phthalazinone derivatives
|
|
TW200825066A
|
|
Phthalazinone derivative
|
|
MY148688A
|
|
2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
|
|
UA96304C2
|
|
2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
|
CN101528724A
|
|
Synthesis of 2-amino-substituted 4-oxo-4H-chromen-8.yl-trifluoro-methanesulfonic acid esters
|
|
WO2007144639A1
|
|
2 -oxybenzamide derivatives as parp inhibitors
|
|
EP2041110A1
|
|
2 -oxyheteroarylamide derivatives as parp inhibitors
|
|
CN101500997A
|
|
PARP inhibitors
|
|
EP1954699A1
|
|
PYRIDO-, PYRAZO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
|
UA96745C2
|
|
PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
|
KR20080063828A
|
|
4-heteroarylmethyl substituted phthalazinone derivatives
|
|
US2007049588A1
|
|
Atm inhibitor
|
|
EP1895997A2
|
|
Use of dna-pk inhibition to sensitise atm deficient cancers to dna-damaging cancer therapies
|
|
UA90716C2
|
|
Dna-pk inhibitors
|
